Polyrizon Ltd. (NASDAQ: PLRZ) Secures U.S. Clinical Site for Allergy Blocker Trial
Key Developments Polyrizon Ltd. (NASDAQ: PLRZ) has achieved a significant milestone by signing its initial Clinical Trial Agreement with a leading U.S. clinical research center specializing in allergy investigations. This critical step advances the company’s development of NASARIX™ (PL-14), its innovative intranasal hydrogel designed to block allergic reactions. This new agreement marks a pivotal point for Polyrizon Ltd. (NASDAQ: PLRZ) as it prepares to transition its NASARIX™ therapy from preclinical…









